Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following allogeneic SCT in first CR, after either myeloablative (MAC) or reduced intensity (RIC) conditioning, will also be evaluated. With an adaptative design, this clinical trial could test up to 3 novel AML agents of interest.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 60 lat
- •Nowo rozpoznana białaczka szpikowa (de novo lub wtórna, na przykład po zespole mielodysplastycznym)
- •Brak wcześniejszego leczenia białaczki (poza hydroksymocznikiem) lub zespołu mielodysplastycznego
- •Stan ogólny pozwalający na leczenie (ECOG ≤ 3)
- •Brak poważnego niekontrolowanego zakażenia
- •Serce zdolne do tolerowania chemioterapii (frakcja wyrzutowa lewej komory ≥ 50%, brak zapaści serca)
- •Prawidłowe wyniki badań wątroby i nerek (chyba że zmienione przez chorobę)
- •Badanie genetyczne genu FLT3 wykonane w laboratorium
✗ Disqualifies
- •Ostra białaczka promielocytarna (APL)
- •Białaczka szpikowa z zaburzeniami in(8;21), t(16;16) lub inv(16)
- •Wtórna białaczka wywodząca się z wcześniejszych zaburzeń rozrostu szpiku
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 61 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (56)
CH Amiens Hôpital Sud
Amiens, France
CHU Angers
Angers, France
CH Victor Dupouy
Argenteuil, France
Centre Hospitalier de la Côte Basque
Bayonne, France
Hôpital Jean Minjoz
Besançon, France
CH Beziers
Béziers, France
Hôpital Avicenne
Bobigny, France
CH Bordeaux
Bordeaux, France
Hôpital du Dr Duchenne
Boulogne-sur-Mer, France
Hôpital Morvan
Brest, France
CH Caen
Caen, France
Clinique du parc
Castelnau-le-Lez, France
Centre Hospitalier René Dubos
Cergy-Pontoise, France
HIA Percy
Clamart, France
CHU Estaing
Clermont-Ferrand, France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France
Hôpital Henri Mondor
Créteil, France
CHU de Dijon
Dijon, France
CH Dunkerque
Dunkirk, France
Hôpital Michallon
Grenoble, France
CH Versailles
Le Chesnay, France
CH Lens
Lens, France
CHRU de Lille, Hôpital Huriez
Lille, France
Hôpital St Vincent de Paul
Lille, France
CHU de Limoges
Limoges, France
Centre Leon Berard (CLB)
Lyon, France
CH Lyon Sud
Lyon, France
Marseille La Conception
Marseille, France
Institut Paoli Calmettes
Marseille, France
CH Meaux
Meaux, France
CHR Metz Thionville_Hôpital de Mercy
Metz, France
Hôpital Saint Eloi
Montpellier, France
CH Mulhouse
Mulhouse, France
CH Hôtel Dieu
Nantes, France
Centre Antoine Lacassagne
Nice, France
CHU Nice
Nice, France
CHRU de Nîmes
Nîmes, France
Hôpital Cochin
Paris, France
Hôpital La Pitié Salpêtrière
Paris, France
Hôpital Necker Enfants Malades
Paris, France
Hôpital Saint Antoine
Paris, France
Hôpital St Louis
Paris, France
Centre Hospitalier Saint Jean
Perpignan, France
CHU de Poitiers
Poitiers, France
Hôpital Robert Debré
Reims, France
CH Pontchaillou
Rennes, France
Hopital Victor Provo
Roubaix, France
Centre Henri Becquerel
Rouen, France
Hôpital René Huguenin
Saint-Cloud, France
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, France
Hôpital Hautepierre
Strasbourg, France
IUCT Toulouse
Toulouse, France
CHU Bretonneau
Tours, France
CH Valenciennes
Valenciennes, France
Hôpitaux de Brabois_CHU Nancy
Vandœuvre-lès-Nancy, France
Institut de Cancérologie Gustave Roussy
Villejuif, France
Trial contact
Mathilde Hunault, PD
DRCI Promotion Interne
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.